Comparative Pharmacology
Head-to-head clinical analysis: DILANTIN 30 versus LYRICA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DILANTIN 30 versus LYRICA.
DILANTIN-30 vs LYRICA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Stabilizes neuronal membranes by promoting sodium channel inactivation, thereby inhibiting repetitive firing of action potentials.
Binds to the α2-δ subunit of voltage-gated calcium channels, reducing calcium influx and inhibiting release of excitatory neurotransmitters including glutamate, norepinephrine, and substance P.
300 mg/day orally in 3 divided doses (100 mg three times daily) or 300 mg/day once daily as an extended-release capsule. Loading dose: 1 g orally divided into three doses (400 mg, 300 mg, 300 mg) given at 2-hour intervals. Intravenous fosphenytoin loading dose: 15-20 mg PE/kg; maintenance: 4-6 mg PE/kg/day IV.
Oral: 75-150 mg twice daily or 50-100 mg three times daily; maximum 600 mg/day. Start at 75 mg twice daily.
None Documented
None Documented
Terminal elimination half-life averages 22 hours (range 7–42 hours) in adults; dose-dependent due to saturable metabolism (Michaelis-Menten kinetics). At low concentrations, half-life is approximately 10–15 hours; at high concentrations, half-life may exceed 30 hours. Clinical context: steady state achieved in 5–10 days; half-life prolonged in neonates, elderly, and hepatic impairment.
Terminal elimination half-life is 6.3 hours (range 5.5–6.7 hours) in patients with normal renal function. Half-life increases in renal impairment (up to 48 hours in anuria).
Renal: ~70% (primarily as inactive metabolites including p-HPPH glucuronide, with <5% unchanged); Biliary/fecal: ~30% (enterohepatic circulation contributes to biliary excretion of metabolites and a small amount of unchanged drug).
Renal excretion of unchanged drug accounts for approximately 90% of elimination; less than 1% is secreted in feces or bile. Dose adjustment required in renal impairment (CrCl <60 mL/min).
Category C
Category C
Anticonvulsant
Anticonvulsant